Research

Landmark study aims to optimize emergency stroke care and improve outcomes for thousands of thrombectomy patients nationwide

Cooper University Health Care, in collaboration with the University of Iowa Health Care, has been awarded research funding by the Patient-Centered Outcomes Research Institute (PCORI) to support a large clinical trial comparing two triage strategies for guiding thrombectomy, a life-saving intervention for patients with large vessel occlusion (LVO) strokes, the most severe and disabling subtype of ischemic stroke. Read more.

The Cooper Foundation recently received a $50,000 donation from Barbara T. Ferraro Ovarian Cancer Research Foundation, which will support ovarian cancer research at MD Anderson Cancer Center at Cooper. This generous contribution marks the second round of funding within a single year, bringing the total support from the Barbara T. Foundation to $100,000.

The funds will help develop the next generation of innovative ovarian cancer treatments by supporting MD Anderson at Cooper’s critical research into the NRF2 and KEAP1 genes, which play a pivotal role in cancer cell resistance to chemotherapy and immunotherapy. Read more.

(Camden, NJ) – Cardiovascular researchers at Cooper University Health Care have discovered a revolutionary new technology that has the potential to fundamentally change how clinicians study heart and vascular function.

Lawrence Mulligan, PhD, FAHA, director of research in the Department of Anesthesiology at Cooper and Associate Professor at Cooper Medical School of Rowan University, in collaboration with Jeffrey Hill, Sc, ACS, FASE, advanced cardiac sonographer and assistant professor of cardiac ultrasound at Massachusetts College of Pharmacy and Health Sciences University in Worcester, Massachusetts, have developed a patent-pending technology called Myocardial Work Quantification, which has the potential to usher in a new era in cardiovascular research. Read more.

Most children with a ‘lazy eye’ benefit from earlier patching, new research by University of Leicester and Cooper Medical School of Rowan University experts show.

Amblyopia (or lazy eye), the most common childhood visual disease, is typically treated by wearing glasses to correct the patient’s vision for a lengthy period of time before patching the eye with better vision to stimulate the weaker eye. Read more.

Internationally known stroke expert Tudor Jovin, MD, medical director of Cooper and Inspira Neuroscience and Professor of Neurology and Neurological Surgery at Cooper Medical School of Rowan University, is the co-principal investigator and co-lead author of a study published today in The New England Journal of Medicine which demonstrates the benefits of treating stroke patients with severe brain damage.

The IN EXTREMIS-LASTE (Large Stroke Treatment Evaluation) study, led by researchers from Montpellier University Medical Center in France (Vincent Costalat, MD, PhD, Professor of Neurology and Chief of Neuroradiology Department and Caroline Arquizan, MD, Chief of Neurovascular Department), in collaboration with researchers from Hospital Foch in Paris, France (Bertrand Lapergue, MD, PhD and Chief of Neurology and Neurovascular Department) and from Cooper University Health Care focused on stroke patients with severe brain damage due to blocked blood vessels without any restrictions in the size of seemingly irreversibly damaged brain as ascertained by brain imaging studies. Read more.

(CAMDEN, NJ) – Researchers at MD Anderson Cancer Center at Cooper are leading the way in new approaches to treating advanced melanoma using tumor infiltrating lymphocyte (TIL) therapy. Earlier this year, MD Anderson at Cooper became the first site in the world to offer and enroll a patient in TILVANCE-301,  a new randomized Phase III clinical trial evaluating the efficacy of TIL therapy as a first line treatment versus pembrolizumab (current standard of immunotherapy care) for advanced melanoma. Read more.

Doctors at Cooper University Health Care are participating in a Department of Defense-funded study that seeks to improve the survival rate of severely injured patients. Prehospital Analgesia INtervention Trial, or PAIN, is a nationwide, phase-3, prehospital clinical trial being led by the University of Pittsburgh that aims to compare the effect of two intravenous (IV) pain medications administered to severely injured patients in the prehospital course of treatment. Read more.